Keri Losavio is the staff editor of The Rheumatologist.
References
- Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: Challenges and prospects for the future. Ther Adv Musculoskelet Dis. 2013 Aug;5(4):210–233.
- Dooley MA, Hogan S, Jennette C, et al. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in Black Americans. Kidney Int. 1997; 51:1188–1195.
- Mok CC, Tang SK. Incidence and predictors of renal disease in Chinese patients with systemic lupus erythematosus. Am J Med. 2004; 117:791–795.
- Bastian HM, Roseman JM, McGwin G Jr, et al, LUMINA Study Group.Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11:152–160.
- Sanchez E, Rasmussen A, Riba L, et al. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian–European populations. Arthritis Rheum. 2012;64:3687–3694.
- Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65:753–763.
- Lupus nephritis. Mayo Clinic. 2025 Jan 31.
- Mok CC, Kwok RCL, Yip PSF. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheumatol. 2013 Aug;65(8):2154–2160.
- Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7.
- FDA approves GSK’s Benlysta as the first medicine for adult patients with active lupus nephritis in the U.S. (news release). GlaxoSmithKline plc. 2021 Dec 17.
- FDA approves Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for adult patients with active lupus nephritis (news release). Aurinia Pharmaceuticals Inc. 2021 Jan 22.
